Trials / Completed
CompletedNCT02587364
Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers
An Oral, Rising, Multiple-Dose Tolerance, Pharmacokinetic and Pharmacodynamic Study of Gemcabene Capsules in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- NeuroBo Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcabene 50 mg | Gemcabene 50 mg once daily (QD) |
| DRUG | Gemcabene 150 mg | Gemcabene 150 mg once daily (QD) |
| DRUG | Gemcabene 450 mg | Gemcabene 450 mg once daily (QD) |
| DRUG | Gemcabene 750/600 mg | Gemcabene 750/600 mg once daily (QD) |
| DRUG | Gemcabene 900 mg | Gemcabene 900 mg once daily (QD) |
| DRUG | Placebo | Placebo once daily (QD) |
Timeline
- Start date
- 1999-04-01
- Primary completion
- 1999-09-01
- Completion
- 1999-09-01
- First posted
- 2015-10-27
- Last updated
- 2020-04-09
Source: ClinicalTrials.gov record NCT02587364. Inclusion in this directory is not an endorsement.